American Society of Hematology
|
|
- Christine Strickland
- 5 years ago
- Views:
Transcription
1 Meeting Highlights American Society of Hematology Walter Alexander The 59th American Society of Hematology (ASH) Annual Meeting, held December 9 12, drew approximately 25,000 hematology professionals to Atlanta. We review below sessions on Hodgkin s lymphoma, diffuse large B-cell lymphoma, venous thromboembolism, hemo philia, sickle cell disease, and chronic lymphocytic leukemia. Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine as Front-Line Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients With Previously Untreated Stage III or IV Hodgkin s Lymphoma: The Phase 3 Echelon-1 Study Joseph M. Connors, MD, Division of Medical Oncology and Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada Results of the multinational, phase 3 Echelon-1 study establish brentuximab vedotin (BV) (Adcetris, Seattle Genetics) plus doxorubicin, vinblastine, and dacarbazine (AVD) as a new first-line option for patients with advanced-stage Hodgkin s lymphoma (HL), Dr. Connors said in an ASH press briefing. Dr. Connors noted that the combination of doxorubicin (formerly referred to by the now-discontinued brand name Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) has been the standard treatment for HL since the 1970s. While other strategies aimed at improving outcomes have all induced severe side effects in phase 1 research, adding the anti-cd30 antibody BV, a microtubule-disrupting agent, to ABVD produced a complete response rate of 96% with 100% five-year overall survival in 26 patients. BV was also well tolerated. In the open-label Echelon-1 study, first-line treatment for stage III or IV HL was administered with ABVD or BV plus AVD in a 1:1 randomization among 1,334 patients with up to 50 months of follow-up. The primary endpoint was modified progression-free survival (mpfs) at two years assessed by independent review. Mean patient age was 68 years in the BV-plus-AVD group and 63 years in the ABVD group, and approximately 58% of the patients in both groups were men. In the BV-plus-AVD group, mpfs was 82.1%; in the ABVD group, it was 77.2% (hazard ratio, 0.77; 95% confidence interval, ; P = ). Subsequent anticancer therapy was required by 18% of patients in the BV-plus-AVD group and by 22% of patients in the ABVD group. Subsequent chemotherapy was required by 33% fewer patients in the BV-plus-AVD group, and 33% fewer received high-dose chemotherapy with transplant in that group. Although grade 3 or higher neutropenia or febrile neutropenia rates were higher in the BV-plus-AVD group, prophylactic use of granulocyte-colony stimulating factor (G-CSF) therapy The author is a freelance writer living in New York City. lowered rates to levels comparable with that of ABVD after the interim safety analysis. In addition, patients receiving BV-plus-AVD had higher rates of treatment-emergent peripheral neuropathy than patients in the ABVD arm (67% versus 43%), with most grade 1 (64%) or grade 2 (29%) in severity. Resolution or improvement by at least one grade was reported in 67% of those with peripheral neuropathy in the BV-plus-AVD group. Drug discontinuation rates for peripheral neuropathy were 7% in the BV-containing arm and 2% in the ABVD arm. Interstitial lung disease of grade 3 or higher, associated generally with bleomycin, occurred in less than 1% of patients receiving BV plus AVD and in 3% of patients receiving ABVD. Brentuximab vedotin in combination with AVD was more effective than ABVD for the front-line treatment of advancedstage Hodgkin s lymphoma, Dr. Connors concluded, adding that chances of being cured with the addition of BV increased as early as the first round of treatment. G-CSF primary prophylaxis is recommended for all patients. He noted that the regimen allows bleomycin to be omitted, and that toxicities are manageable. Primary Analysis of JULIET: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania Analysis of JULIET trial results reveals a high percentage of durable response to tisagenlecleucel (Kymriah [formerly CTL019], Novartis) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In an ASH press briefing, Dr. Schuster said the trial also showed that global distribution of tisagenlecleucel, the first chimeric antigen receptor T-cell therapy to be approved, is feasible. He noted that responses to salvage therapy in this poorprognosis relapsed/refractory population are historically low (8% complete response [CR], 18% partial response [PR]). Median overall survival is just four months. High-dose chemotherapy followed by autologous stem cell transplant is the standard of care. Approximately 50% of patients are ineligible for transplant, and about another 25% respond to chemotherapy and can go on to transplantation. Among these patients, approximately 10% are cured and 15% relapse. Most patients who relapse have no further options. In a phase 2 study of tisagenlecleucel, all CRs (57%) were sustained at a median follow-up of 29 months. Manufacturing of tisagenlecleucel with cryopreserved apheresis was centralized in the pivotal JULIET trial. The drug was distributed to 27 sites in 10 countries in North America, Europe, Australia, and Asia. Investigators enrolled 99 patients with DBLCL who were ineligible for transplant or who had disease that had progressed after two or more lines of prior chemotherapy. Twenty-six percent of patients were treated on an outpatient basis. Vol. 43 No. 2 February 2018 P&T 111
2 The primary endpoint of overall response rate (ORR) (CR plus PR) in 81 evaluable patients was 53% with CR in 40% (P < ). At three months (n = 81), ORR was 38% and CR was 32%. At six months (n = 46), the rates were 37% and 30%, respectively. Dr. Schuster commented that the durability of response is shown by the stability between three- and six-month response rates. In addition, 74% of responders were relapsefree at six months. While in response, no patients proceeded to transplant. Most adverse events occurred shortly after infusion and included cytokine release syndrome (58%) and neurotoxicities (21%). No deaths were attributed to adverse events. Analysis confirms the durable clinical benefit previously observed in the single-center University of Pennsylvania trial, Dr. Schuster said. We are going to be able to offer patients who don t respond to standard therapies a form of therapy that may, after a single treatment, relieve symptoms and save lives. A Randomized, Open-Label, Blinded-Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin For Venous Thromboembolism Associated With Cancer: The Hokusai VTE-Cancer Study Gary E. Raskob, PhD, University of Oklahoma College of Public Health, Oklahoma City, Oklahoma In the Hokusai VTE-Cancer study, oral edoxaban (Savaysa, Daiichi Sankyo) was noninferior to subcutaneous dalteparin (Fragmin, Pfizer) for the endpoint of venous thromboembolism (VTE) or major bleeding. While recurrent thromboembolism was reduced with edoxaban, major bleeding increased to a similar degree, Dr. Raskob said. At an ASH late-breaking clinical trial session, he pointed out that roughly one in five individuals with cancer develop thromboembolism, a rate higher than in patients without cancer. Bleeding also occurs more often in cancer patients, he said, and can both interfere with cancer therapy and contribute to mortality and morbidity. Major practice guidelines, including those from the American College of Chest Physicians, American Society of Clinical Oncology, and European Society for Medical Oncology, recommend low-molecular-weight heparin (LMWH) as initial and long-term therapy for VTE, but subcutaneous injections can be burdensome and limit adoption of therapy. Direct oral anticoagulants, such as edoxaban, may be an attractive alternative for these patients, Dr. Raskob said. The 1,050 patients enrolled in the Hokusia VTE-Cancer study represented a wide range of cancer types and chemotherapy regimens; approximately 10% had hematologic cancers and the rest had solid tumors. All were being treated for VTE (at 114 centers in 13 countries). Half were randomly assigned to receive LMWH (dalteparin 200 IU/kg daily for one month, then 150 IU/kg thereafter), and half were assigned to receive edoxaban (60 mg daily) for up to 12 months. All patients were followed for 12 months or until study closure (minimum, nine months). The primary outcome was first recurrent VTE or major bleeding event at 12 months. Dr. Raskob reported that the primary outcome rate was significantly lower in the edoxaban group than in the dalteparin group (12.8% versus 13.5%) (hazard ratio, 0.97; 95% confidence interval, ; P = 0.018). The recurrent VTE rates for edoxaban and dalteparin were 6.5% and 10.3%, respectively. The major bleeding rates were 6.3% and 3.2%, respectively. Most bleeding was in the upper gastrointestinal tract and occurred in patients with gastrointestinal cancers, Dr. Raskob said. While the major bleeding rate was higher for edoxaban, bleeds in the dalteparin group tended to be more severe. Event-free survival was identical for both groups. Oral edoxaban is noninferior to subcutaneous dalteparin for the primary outcome of recurrent venous thromboembolism or major bleeding, Dr. Raskob said. He explained that the results do not necessarily apply to all direct oral anticoagulants because some act through different mechanisms or are metabolized differently than edoxaban. For the vast majority of patients with cancer-associated venous thromboembolism, treatment with oral edoxaban can replace the injectable dalteparin, he concluded. HAVEN 2 Updated Analysis: Multicenter, Open-Label Phase 3 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Subcutaneous Emicizumab Prophylaxis in Pediatric Patients With Hemophilia A With Inhibitors Guy Young, MD, University of Southern California Keck School of Medicine, Children s Hospital Los Angeles, Los Angeles, California In children with hemophilia A who develop resistance to standard intravenous (IV) therapy, once-weekly subcutaneous (SC) administration of emicizumab (Hemlibra, Genentech) effectively prevents bleeds, according to nine-week results of the HAVEN 2 trial presented at an ASH press conference. In patients with hemophilia A, the most common form of the disease, levels of blood-clotting protein factor VIII are extremely low, leading to debilitating bleeding events, with joint pain and eventual joint disease in the absence of factor VIII infusions. In about 30% of patients, however, neutralizing alloantibodies (known as inhibitors) bind to the infused factor VIII and render it useless. Morbidity increases and health-related quality of life declines. The condition is currently treated through immune tolerance induction or bypassing agents requiring frequent IV infusions, often with long-term use of central venous access devices in children, with concomitant infections and thrombosis. The unmet need in this population, Dr. Young said, is to alleviate the burden of both the disease and the treatment. Emicizumab, a humanized, bispecific, monoclonal antibody, is not affected by inhibitors and replaces the function of factor VIII by bridging activated factor IX and factor X. Children in HAVEN 2 (N = 60, 100% male) all have inhibitors to factor VIII infusions. They are receiving episodic or prophylactic treatment with bypassing agents. They are being treated with SC emicizumab at 3 mg/kg per week for four weeks and 1.5 mg/kg per week thereafter. The primary analysis will be conducted 52 weeks after the last patient is enrolled. Safety will be monitored for 24 additional weeks (on or off study drug). Dosing intervals of two and four weeks will be tested in future trials. 112 P&T February 2018 Vol. 43 No. 2
3 At baseline, 95% of the boys had severe disease. The median number of bleeds per patient in the 24 weeks preceding the trial was six (range, 0 155). In addition, more than one-third of the patients (38.3%) had target joints (joints with frequent bleeding episodes). Emicizumab treatment was effective in this population. Among 57 evaluable patients, 94.7% reported zero bleeds needing treatment, and 98.2% had no treated joint bleeds. Among the 23 patients with at least 12 weeks of follow-up (range, weeks), only three patients reported treated bleeds (one each in the joint, muscle, and hip). All three were safely treated with recombinant factor VIIa, a standard of care for this population. The annualized bleeding rate in this group was 0.2, a 99% reduction compared with prior bypass agent prophylaxis. Health-related quality of life for patients and burden for caregivers versus prior bypassing agents were both substantially improved. Ten of the 40 adverse events (67.7%) were considered treatment-related. All were local injection-site reactions: six of them serious and four of grade 3 or higher. No thromboembolic or thrombotic microangiopathy events were reported. Emicizumab successfully prevented or reduced bleeds, Dr. Young concluded. The once-weekly treatment is so much easier for the patients. This treatment has a tremendous impact on patients lives. Achievement of Normal Circulating Factor VIII Activity Following BMN 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results From a Phase 1/2 Study in Patients With Severe Hemophilia A K. John Pasi, MD, Barts and the London School of Medicine and Dentistry, London, United Kingdom In a first-in-human phase 1/2 study, patients with hemo philia A who underwent an investigational, single-infusion gene therapy using an AAV-factor VIII vector (valoctocogene roxaparvovec [formerly BMN 270], BioMarin) have experienced sustained and clinically relevant factor VIII activity for more than 1.2 years after treatment. Valoctocogene roxaparvovec is a functional copy of the gene responsible for producing factor VIII; this gene is mutated in hemophilia A patients. The results have profoundly reduced self-reported bleeding and exogenous factor VIII use in these patients, Dr. Pasi said. He also said that hemophilia A, an X-linked, single-gene disorder of factor VIII, is an ideal candidate for gene therapy. The current treatment standard for severe hemophilia A (factor VIII level of less than 1 IU/dL) of using factor VIII replacement products is expensive and demanding, requiring multiple intravenous infusions per week. While several gene therapies have demonstrated success for hemophilia B, the rarer form of the disease, gene therapy for hemophilia A has been considered more challenging because it is associated with a more complex and much larger gene. Participants had received up to 185 factor VIII infusions to prevent bleeds in the year prior to study enrollment, with up to 41 breakthrough bleeding episodes per year despite prophylactic treatment. Patients received one of four valoctocogene roxaparvovec doses based on factor VIII activity at three weeks, with doses increased if their factor VIII level was less than 5 IU/dL. Dr. Pasi reported results from two of the valoctocogene roxaparvovec doses (6E13 vg/kg, n = 7; 4E13 vg/kg, n = 6). Within several weeks of treatment, all patients began producing factor VIII. By 20 weeks after the infusion, factor VIII levels in those receiving the higher dose had plateaued in the normal range and remained there. Among those receiving the lower dose, factor VIII levels increased steadily to a median of 34 IU/dL by week 20. In three patients who had been followed for 32 weeks, the factor VIII median was 51 IU/dL, which is within the normal range. Dr. Pasi observed that with 1.5 years of follow-up, 6E13 vg/kg achieved levels within the normal range of factor VIII activity, with a median of 90 IU/dL at 78 weeks. With up to one year of follow-up, 4E13 vg/kg achieved levels approaching or within the lower end of the normal range of factor VIII activity, with a median of 49 IU/dL at 48 weeks (n = 3). The increases, given that pretreatment factor VIII levels were less than 1 IU/dL, were dramatic, he said. In those patients with post-infusion factor VIII levels greater than 5%, the annualized bleed rate in the 6E13 group went from 16.5 episodes to zero, and from eight to zero episodes in the 4E13 group. Similarly, in those with post-infusion factor VIII levels greater than 5%, median annual factor VIII use dropped from infusions to zero in the 6E13 group and from infusions to zero in the 4E13 group. Valoctocogene roxaparvovec was well tolerated, Dr. Pasi said, and no patients developed inhibitors to factor VIII. Two serious adverse events included pyrexia with myalgia and headache during infusion and a planned total knee replacement for chronic arthropathy. Nonserious liver enzyme elevations of limited duration ( weeks) were observed in 10 of 15 patients. In addition, all patients who received 6E13 remain off steroids, and only one 4E13 patient remains on steroids. Dr. Pasi said that adverse events were not qualitatively different between the 6E13 and 4E13 cohorts. Both doses of valoctocogene roxaparvovec eliminated occurrence of spontaneous bleeds and provided factor VIII coverage, eliminating the need for factor VIII, even in cases of major trauma or surgery, he concluded. Long-Term Follow-Up in ZUMA-1: A Pivotal Trial Of Axicabtagene Ciloleucel in Patients With Refractory Aggressive Non-Hodgkin s Lymphoma Sattva S. Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas More than half of patients with fast-growing and refractory aggressive non-hodgkin s lymphoma were alive at least one year after a single infusion of axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) in the pivotal ZUMA-1 trial. Axicabtagene ciloleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the CD19 protein often found on lymphoma cells, Dr. Neelapu said in an ASH press briefing. A patient s own T cells are harvested for CAR T-cell therapies, and then reengineered to target specific proteins on leukemia Vol. 43 No. 2 February 2018 P&T 113
4 and lymphoma cell surfaces. They are then reintroduced to the patient s immune system, Dr. Neelapu explained. The phase 1/2 ZUMA-1 study, conducted at 22 sites, is the largest study of a CAR T-cell therapy to date. ZUMA-1 includes seven phase 1 patients and 101 phase 2 patients (median age, 58 years; age range, years; 68% men), all of whom had not responded to their last chemotherapy or had relapsed after it. Patients were a year or less post-autologous stem cell transplant and had received prior anti-cd20 monoclonal antibody and anthracycline treatment. Seventy percent of the patients had received three or more prior therapies. The objective response rate in the 108 patients was 82%, including 58% with a complete response (CR) after a median follow-up of 15.4 months. Forty-three percent (three of seven) of the phase 1 patients have achieved a CR, which is ongoing at 24 months. In the updated analysis, 23 of 60 patients with either a partial response (11 of 35) or stable disease (12 of 25) at the first tumor assessment (one month post-infusion) subsequently achieved a CR up to 15 months after infusion without additional therapy. Median duration of response has not been reached in those with a CR and is 11.1 months in the overall group. Among the 56% of patients remaining alive, 42% are progression-free, Dr. Neelapu said. Most patients (97%) had a grade 3 or higher adverse event, with cytokine release syndrome, neurological toxicities, neutropenia, anemia, and thrombocytopenia most common in the pivotal portion of ZUMA-1. Within six months after the primary analysis, 10 patients experienced a serious adverse event, with manageable infections in eight patients. In the updated analysis, no new-onset cytokine release syndrome or neurological events related to axicabtagene ciloleucel were observed. Investigators found, after analyzing tumor tissue biopsied before and after treatment in patients who relapsed, that more than two-thirds of tumors showed evidence of programmed death ligand-1 expression that was likely inhibiting the function of the infused T cells. Follow-up studies are now under way. Axi-cel [axicabtagene ciloleucel] is highly effective in patients with large B-cell lymphoma who otherwise have no curative options, Dr. Neelapu said. Initial Results From a Cohort in a Phase 2a Study Evaluating Adolescents With Sickle Cell Disease Treated With Multiple Doses of GBT440, an HbS Polymerization Inhibitor Carolyn C. Hoppe, MD, Children s Hospital Oakland, Oakland, California Improvements in total severity scores suggest that voxelotor (formerly GBT440, Global Blood Therapeutics, Inc.) may be a disease-modifying therapy for patients with mildly symptomatic sickle cell disease. That conclusion emerged from interim study findings, Dr. Hoppe said in an ASH press briefing. Voxelotor, an investigational first-in-class hemoglobin oxygen affinity modulator, inhibits the intracellular polymerization of sickle hemoglobin that makes red blood cells less deformable, leading to hemolytic anemia, vaso-occlusion and symptoms of fatigue, pain crisis, and potentially fatal organ damage. Dr. Hoppe reported on a phase 2a, open-label, 24-week study designed to assess the efficacy of voxelotor in pediatric patients with sickle cell disease as measured by improvements in anemia. Prior voxelotor testing, she noted, had only been among adults. The current trial included 24 adolescents (ages years) with sickle cell disease. All received voxelotor 900 mg daily. The efficacy analysis was conducted among 12 patients (half were female) who had undergone 16 weeks of treatment. Most (11 of 12) had the HbSS genotype. Forty-one percent of the children had experienced one to four vaso-occlusive crises in the prior year, and 55% had been vaso-occlusive crisis-free. Eleven had been receiving hydroxyurea, the standard of care. Hemoglobin responses greater than 1 g/dl at week 16 were achieved by 55% (six of 11) of the patients. Ten of 12 patients showed a reduction in total severity score from baseline, and five of 12 had a mean total severity score of zero at week 16. One patient sustained a score of zero from baseline to week 16. Voxelotor was well tolerated with most adverse events grade 1 or 2 in severity (nausea, 12.5%; headache, 8.3%; rash, 8.3%). No drug-related serious adverse events or study drug discontinuations were reported. Voxelotor 900 mg for 16 weeks in sickle cell disease adolescents, most of whom were receiving hydroxyurea, demonstrated consistent and sustained efficacy on hemoglobin levels and measures of hemolysis, Dr. Hoppe said. The findings also suggest that voxelotor s safety and tolerability profile are consistent with that demonstrated among adults in the earlier study. Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study Of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura Marie Scully, MD, Department of Hematology, University College London Hospitals NHS Trust, London, United Kingdom Results of the phase 3 HERCULES study confirm that treatment with caplacizumab (investigational, Ablynx) reduces the time to platelet count response, resulting in faster resolution of acquired thrombotic thrombocytopenic purpura (attp). The findings, Dr. Scully said in a late-breaking clinical trial presentation, confirm the promising data from earlier-stage research. Acquired thrombocytopenic purpura, an acute life-threatening thrombotic microangiopathy, Dr. Scully noted, occurs when antibodies block the activity of ADAMTS-13, an enzyme that cleaves von Willebrand factor, a key blood-clotting protein. Disseminated microthrombi deprive tissues of oxygen, causing end-organ damage with greater than 90% mortality in the absence of treatment. The current treatment for attp is daily plasma exchange to remove autoantibodies, and corticosteroids and/or rituximab (Rituxan, Genentech) to inhibit autoantibody formation. Mortality is 10% to 20%, and the disease recurs within weeks after the cessation of plasma exchanges. The unmet medical need remains high, Dr. Scully said. The anti-von Willebrand nanobody caplacizumab inhibits the formation of microthrombi by blocking the binding of von Willenbrand factor to platelets, Dr. Scully explained. It was tested in the double-blind, multinational HERCULES study, which included 145 patients suffering acute episodes of attp 114 P&T February 2018 Vol. 43 No. 2
5 despite standard care. Half were given caplacizumab and the other half placebo. Treatment was administered intravenously before plasma exchange, with daily doses given subcutaneously for the duration of the daily plasma exchange, and 30 days thereafter. Treatment could be extended for up to an additional four weeks if the underlying disease was ongoing. Patients were monitored for safety for at least 28 days post-treatment. The primary endpoint was time to platelet count response (initial platelet count /L or greater with subsequent cessation of daily plasma exchange within five days). Dr. Scully reported a platelet normalization rate ratio of 1.55 for patients receiving caplacizumab (95% confidence interval, ; P < 0.01). The first key secondary endpoint of attprelated death, recurrence, or major thromboembolic event was reported at rates of 49.3% for placebo (n = 73) and 12.7% (n = 72) for the caplacizumab group. The recurrence rate of attp was 38.4% and 4.2% in the placebo and caplacizumab groups, respectively. Similar percentages of patients in the placebo (8.2%) and caplacizumab (8.5%) groups experienced at least one emergent major thromboembolic event. Deaths attributed to attp were reported at a rate of 4.1% in the placebo group and 0% in the caplacizumab group. In addition, patients in the caplacizumab group experienced improvements in the relative reduction of days of plasma exchange ( 38%), plasma volume ( 41%), days in intensive care ( 65%), and days in the hospital ( 31%). Rates of treatment-emergent adverse events leading to discontinuation were 12.3% and 7.0% in the placebo and caplacizumab groups, respectively. The safety profile of caplacizumab was in line with prior study reports, Dr. Scully said. She concluded, Caplacizumab addresses the pathophysiological platelet aggregation that leads to the formation of microthrombi and the resultant mortality and morbidity seen in attp. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Results From Preplanned Interim Analysis of the Randomized Phase 3 Murano Study demonstrated an acceptable safety profile with high rates of complete response and minimal residual disease (MRD) negativity, and with durable disease control after drug cessation. MURANO investigators enrolled 389 patients (median age, 65 years) whose CLL had persisted or recurred after at least one previous course of treatment, including chemotherapy. Half of the patients were randomly assigned to a regimen of six monthly doses of venetoclax (400 mg daily) plus rituximab (375 mg/m 2 day 1 of cycle 1; 500 mg/m 2 day 1 of cycles 2 6) and half received six cycles of bendamustine (70 mg/m 2 days 1 and 2 of cycles 1 6) plus rituximab. Patients assigned to the venetoclax arm continued to use venetoclax alone for two years or until CLL returned. The primary endpoint was investigator-assessed PFS. After a median follow-up of 23.8 months (range, months), median PFS was not reached in the venetoclax group and was 17 months in the bendamustine group (hazard ratio [HR], 0.17; 95% confidence interval [CI], ; P < ). In the venetoclax group, 65 patients completed two years of treatment without progression. Overall survival at two years was 91.9% and 86.6% in the venetoclax and bendamustine groups, respectively (HR, 0.48; 95% CI, ; P = ). The improvements, Dr. Seymour said, were clinically meaningful. Safety was consistent with known safety profiles in patients with relapsed/refractory CLL, he said. Serious adverse events were reported in similar proportions in both groups (46% for venetoclax plus rituximab; 43% for bendamustine plus rituximab), with grade 3 and grade 4 event rates of 82% and 70%, respectively. MURANO results suggest that venetoclax plus rituximab should be considered as a standard therapeutic option in patients with relapsed/refractory CLL, replacing chemotherapy, Dr. Seymour concluded. The results also indicate that the preferred treatment would be with venetoclax in combination with rituximab, he said. REFERENCE 1. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29(26): n John F. Seymour, MBBS, PhD, Peter MacCallum Center and Royal Melbourne Hospital, Melbourne, Australia MURANO, the first phase 3 study of venetoclax (Venclexta, AbbVie) in relapsed/refractory chronic lymphocytic leukemia (CLL), shows a profound improvement in progression-free survival (PFS) versus standard bendamustine chemotherapy with rituximab (Rituxan, Genentech), with consistent effects across all risk subsets, Dr. Seymour said in a late-breaking clinical trial press briefing. With historical overall response rates of 59%, complete response rates of 9%, a median PFS rate of 15.2 months, and overall survival of 33.9 months, 1 the conventional chemoimmunotherapy combination of bendamustine and rituximab is suboptimal, Dr. Seymour noted. Venetoclax is an orally administered, highly selective, potent BCL-2 inhibitor with activity even in patients with poor prognostic features. Phase 1b research with venetoclax combined with rituximab, however, Vol. 43 No. 2 February 2018 P&T 115
State of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationTreating breakthrough bleeds: A new approach
Treating breakthrough bleeds: A new approach Using Bypassing Agents With HEMLIBRA Prophylaxis Indication HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
More informationHemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW
Hemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW Introduction Brand name: Hemlibra Generic name: Emicizumab-kxwh Pharmacological class: Bispecific factor IXa- and factor X-directed antibody Strength and
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationMedia Release. Basel, 12 December 2017
Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationMedia Release. Basel, 10 December 2017
Media Release Basel, 10 December 2017 Phase II data showed Roche s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMedia Release. Basel, 5 December 2016
Media Release Basel, 5 December 2016 Roche s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationInterim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII gene transfer in severe haemophilia A
Interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII gene transfer in severe haemophilia A John Pasi 1, Savita Rangarajan 2, Liron Walsh 3, Will Lester 4, David Perry 5, Bella Madan
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationHEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH INHIBITORS
HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH INHIBITORS Media Inquiries: (650) 467-6800 About HEMLIBRA HEMLIBRA (emicizumab-kxwh) is approved by the FDA as a prophylactic medicine used to prevent or
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationHEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS
HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS Media Inquiries: (650) 467-6800 About Hemlibra Hemlibra (emicizumab-kxwh) is approved by the FDA as a prophylactic (preventative)
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationMedia Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationHighlights from the 2017 Annual Meeting of the American Society of Hematology
Latest NEWS IN BLOOD CANCER RESEARCH Highlights from the 2017 Annual Meeting of the American Society of Hematology CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationBR for previously untreated or relapsed CLL
1 Protocol synopsis Title Rationale Study Objectives Multicentre phase II trial of bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationCAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability. Julie M. Vose, MD, MBA
CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability Julie M. Vose, MD, MBA Relevant Disclosures Research Funding: Kite Pharma/Gilead, JUNO/Celgene, Novartis Honorarium/Ad Boards: Novartis,
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationProduct: Blinatumomab Clinical Study Report: MT Date: 11 July 2014 Page 1
Date: 11 July 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich) GmbH Name of Finished Name of Active Ingredient: Blinatumomab, a murine recombinant single-chain antibody derivative that
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationThrombotic thrombocytopenic purpura: a look at the future
Thrombotic thrombocytopenic purpura: a look at the future Andrea Artoni, MD Ph.D. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, Italy andrea.artoni@policlinico.mi.it
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More informationChimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma
Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationCHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma
Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationThe First rfviii WITH A PROLONGED HALF-LIFE
Visit ELOCTATEpro.com for more information The First rfviii WITH A PROLONGED HALF-LIFE Indications ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationRoche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia
Media Release Basel, 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia Venclexta is designed to help
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationMaking Hope A Reality December 10, Nasdaq : BLUE
Making Hope A Reality December 10, 2014 Nasdaq : BLUE Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationImmunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
Immunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy This transcript has been edited for style and clarity and includes all slides from the presentation. This
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationHematologic Malignancies: Top Ten Advances Impacting Clinical Practice
Hematologic Malignancies: Top Ten Advances Impacting Clinical Practice Adam D. Cohen, MD Abramson Cancer Center University of Pennsylvania June 14, 2018 Please note that some of the studies reported in
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationScottish Medicines Consortium
Scottish Medicines Consortium romiplostim, 250 microgram vial of powder for solution for subcutaneous injection (Nplate ) No. (553/09) Amgen 08 May 2009 (Issued 4 September 2009) The Scottish Medicines
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationFDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Media Release Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,
More informationMedia Release. Basel, 21 May 2018
Media Release Basel, 21 May 2018 Roche s Hemlibra reduced treated by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors In a subset of patients
More informationInvestor Update. Downloads. Services PDF. Basel, 23 June 2017
Investor Update Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationbrentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd
brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationChimeric Antigen Receptor - CAR T cell therapy. Frederick L. Locke, MD 2/17/2017
Chimeric Antigen Receptor - CAR T cell therapy Frederick L. Locke, MD 2/17/2017 T cells are immune system cells that normally fight infection Each T cell recognizes a specific target T cells multiply and
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
brentuximab. Given that the median survival of Hodgkin lymphoma patients who relapse after ASCT is approximately two years, perc considered that the manufacturer had substantially overestimated the incremental
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More information